- March 27, 2019: Pain Therapeutics Inc. (PTIE) said it was changing its name and ticker to better reflect its focus on developing drugs for neurodegenerative diseases such as Alzheimer's..
- The company was in a phase 2 testing of a drug candidate aimed at treating Alzheimer's, that did not seek to clear amyloid from the brain, but rather to stabilize a critical protein in the brain. It was also working to develop a biomarker/diagnostic to detect Alzheimer's using a simple blood test.
June 28, 2024
Hoau-Yan Wang, a professor at the City University of New York (CUNY), was charged with fraud of over $16 million in grants.
He co-wrote numerous articles with Cassava supporting the scientific rationale for Alzheimer’s drug candidate called simufilam.
The drug is currently undergoing late-stage testing as an Alzheimer’s treatment.
He co-wrote numerous articles with Cassava supporting the scientific rationale for Alzheimer’s drug candidate called simufilam.
The drug is currently undergoing late-stage testing as an Alzheimer’s treatment.
Back when it was Pain Therapeutics, Cassava pushed an opioid called Remoxy. A 2022 New Yorker piece about CEO Remi Barbier and whistleblowers detailed some of its problems. Cassava’s clinical data was manipulated, a whistleblower said.
- 7 months later:
Feb 7, 2025
